Ypsomed Holding Ag · SIX:YPSN
Ypsomed — FY2024/25 Earnings Presentation
41 slides from Ypsomed's earnings presentation, May 21, 2025
Slide 1: Ypsomed Full Year Results 2024/25
Ypsomed Full Year Results 2024/25 Transforming selfcare, Transforming Ypsomed Zurich, 21 May 2025
Slide 2: Important information
Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or op
Slide 3: Making selfcare simpler and easier
Making selfcare simpler and easier 3 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 4: Our growth drivers provide exciting opportunities
Our growth drivers provide exciting opportunities Selfcare Enhancing quality of life, encouraging therapy adherence and facilitating more efficient healthcare systems Biologics Most new generation drugs with complex active pharmaceutical ingredients must be injected Biosimilars Expanding globa
Slide 5: 5 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
5 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 6: Unlocking full potential
Unlocking full potential Ypsomed is evolving into Diabetes Care is evolving a pure B2B company into a pure B2C that focuses on expanding company with a patient- its leading position in centric culture self-injection therapies 6 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 7: TecMed has a strong strategic fit for Ypsomed Diabetes Care
TecMed has a strong strategic fit for Ypsomed Diabetes Care TecMed is the ideal owner for Ypsomed Diabetes Care Providing long-term commitment and a clear vision TecMed guarantees stability for all stakeholders TecMed is the owner of a patch pump program 7 | Ypsomed Holding AG | Full year re
Slide 8: Ypsomed becomes a focused pure-play injection systems specialist
Ypsomed becomes a focused pure-play injection systems specialist 2022 Transformation from matrix to business areas with Ypsomed Next 2023 Completion of the sale of the DiaExpert retail business in Germany 2024 Completion of the sale of the pen needle and BGM business 2024 Decision to sell the Diabet
Slide 9: Ypsomed's new starting point – Delivery Systems revenue of CHF 501 million
Ypsomed's new starting point – Delivery Systems generated revenue of CHF 501 million in the FY 2024/25 Sales contribution Sales contribution FY 2024/25 mid-term 11 237 501 Delivery Systems Diabetes Care Other 9 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 10: 10 | Ypsomed Holding AG | Full year results 2024/25
10 | Ypsomed Holding AG | Full year results 2024/25
Slide 11: Ypsomed Delivery Systems focusses on solutions built on platforms
Ypsomed Delivery Systems focusses on solutions built on platforms 11 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 12: Ypsomed platform business model broadens access to self-injection devices
Ypsomed platform business model broadens access to self-injection devices, reduces development risk and accelerates time to market 12 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 13: Another strong increase in sales for Delivery Systems
Another strong increase in sales of 30 % for Delivery Systems Revenues Ypsomed Delivery Systems 501 Growth trajectory 548.5 102 Strong top-line growth of 30 % 311 74 385 399 Above average sales growth of 50 % for commercial autoinjectors 36 additional projects acquired with in million CHF exis
Slide 14: Ypsomed broad product portfolio secures new project wins in 2024/25
Ypsomed broad product portfolio secures 36 new project wins in 2024/25 Commercial sales Acquisitions Acquisitions (36 new (total) by platform (36 new projects) by platform projects) by customer segment Autoinjectors Pens Autoinjectors Pens Existing Customers New Customers 14 | Ypsomed Holding AG | F
Slide 15: Covering a wider range of disease areas – Three new disease areas added
Covering a wider range of disease areas – Three new disease areas added Pens Autoinjectors Diabetes Asthma Osteoporosis Fertility Atopic dermatitis Psoriasis Growth disorders ATTR amyloidosis Rheumatoid arthritis Obesity Hypercholesterolemia Hereditary angioedema Osteoporos
Slide 16: GLP-1's are expected to contribute to further revenue growth
GLP-1's are expected to contribute to further revenue growth Ypsomed Emerging Global Asset diversity with 47 deals (34 clients) pipeline market market Originators 5 7 Balanced asset portfolio between originators and biosimilars Biosimilars 18 17 Expected launch times for the deals extend over
Slide 17: Ypsomed is active in over 130 projects with a diverse range of clients
Ypsomed is active in over 230 projects with a diverse range of 130 clients Demonstrating our well-diversified portfolio 77 40 40 No. accounts No. projects diseases Obesity/ vascular Insulin Oncology Autoimmune therapies GLP-1 Neurology Infectious Diabetes/ Diabetes/ Hormone Rare Cardio- 17 | Ypsomed
Slide 18: New injector projects on the rise in a market moving towards larger volumes
New injector projects on the rise in a market moving towards larger volumes Pre-filled and pre-assembled platform portfolio philosophy Launch of first YpsoMate 2.25 Pro with constant force spring for higher viscosities YpsoMate 5.5 industrialised for small batch production YpsoDose productio
Slide 19: Significant capacity added in 2024/25
Significant capacity added in 2024/25 120 million units/year additional assembly capacity qualified and commissioned 4 additional assembly lines and 38 additional injection moulding machines qualified and commissioned Capacity disposable units per year: ~300 million (without Contract Manufactu
Slide 20: Schwerin – Additional hall D
Schwerin 1 – Additional hall D With a total capacity of up to 250 million devices p.a. 20 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 21: Schwerin – Up to 500 million additional devices p.a.
Schwerin 2 – Up to 500 million additional devices p.a. Opening in two phases 2026 and 2028, and LEED-Gold standard certified 21 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 22: Schwerin – Groundbreaking ceremony for our new manufacturing site
Schwerin 2 – Groundbreaking ceremony for our new manufacturing site 22 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 23: Changzhou – Ypsomed's first own factory in China opening in June 2025
Changzhou 1 – Ypsomed’s first own factory in China opening in June 2025 23 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 24: Changzhou – Ypsomed China built a state-of-the-art manufacturing facility
Changzhou 1 – Ypsomed China built a state-of-the-art manufacturing facility 24 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 25: Ypsomed goes to the USA – Opening in H2 2027
Ypsomed goes to the USA – Opening in H2 2027 Ypsomed has decided to invest in a new North Carolina manufacturing plant in the USA Our presence in this market will increase supply chain security and make a positive contribution to our and our customer’s sustainability goals The establishment of
Slide 26: Significant expansion of Ypsomed's global manufacturing footprint
Significant expansion of Ypsomed’s global manufacturing footprint North America Schwerin (D) Schwerin II (D) opening 2027 opening 2026 Burgdorf HQ (CH) Solothurn (CH) Burgdorf (CH) Burgdorf (CH) Suzhou (CN) Changzhou (CN) (Contract Manufacturer) 26 | Ypsomed Holding AG | Full year results 2024/25 PU
Slide 27: Number of employees
Creating 364 new jobs in 12 months, thereof 180 in Switzerland 2 753 744 2 753 Other 2 389 Diabetes Care 2 059 Delivery Systems 1 923 DiaExpert GmbH 1 854 Number of employees 791 752 Abroad production and R&D 687 728 628 Abroad sales 1 016 875 781 Solothurn Bern 2021/22 2022/23 2023/24 2024/25 2024/
Slide 28: 28 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
28 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 29: Sales of CHF 501 million in our continued business – a new starting point
Sales of CHF 501 million in our continued business – a new starting point Sales FY 2024/25 Reported EBIT FY 2024/25 –34 167 11 –20 237 113 in million CHF 501 YDS YDC EBIT 2024/25 YDS Other YDC Reported Other 29 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 30: Revenues Ypsomed Group
in million CHF 2023/24 reported 548 PN & 30 | Ypsomed Holding AG | Full year results 2024/25 BGM -39 2023/24 w/o PN & 509 BGM Revenues Ypsomed Group Growth YDS 116 Growth YpsoPump 78 Strong operating sales growth of 37 % PUBLIC Decline Ypsotec –1 2024/25 guided 702 PN & BGM 28 TecMed contract 19 202
Slide 31: EBIT Ypsomed Group
in million CHF 2023/24 reported 86 PN & 31 | Ypsomed Holding AG | Full year results 2024/25 BGM 12 2023/24 EBIT Ypsomed Group w/o PN & 99 BGM Growth YDS 22 Growth YpsoPump 23 Strong operating EBIT growth of 43 % PUBLIC Decline Ypsotec –3 2024/25 guided 141 PN & BGM –32 Impairment Ypsotec –14 TecMed
Slide 32: Investment focus on growth CAPEX
Investment focus on growth CAPEX Cash flow Ypsomed Group Cash flow Strong operational cash flow 148 –267 Significant rise in investments in capacity expansions Investments in intangible assets in million CHF –119 remain stable –37 82 financing CF from FCF Total CF CF from investment CF from op
Slide 33: CHF million growth investments in infrastructure and R&D
CHF 272 million growth investments in infrastructure and R&D Providing the foundation for future growth in line with global investment program Fixed assets 202 202 70 272 Expansion of capacities for YpsoMate 80 201 and UnoPen 80 178 Expansion of operating infrastructures in Switzerland, Germany
Slide 34: Ypsomed invests to meet growing demand
We have achieved a ROCE of around 20 % in Delivery Systems Ypsomed invests to meet growing demand: We unveiled our global investment program of CHF 1.5 billion We achieved a ROCE of ~20 % in the Delivery System business 34 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 35: Proceeds from Diabetes Care sale to fund Delivery Systems business growth
Proceeds from Diabetes Care sale to fund Delivery Systems business growth The total proceeds of the transaction is up to CHF 420 million (including earn-out) Ypsomed will reinvest the proceeds to further expand its Delivery Systems business No special dividend will be paid 35 | Ypsomed Holding
Slide 36: Ypsomed has strong fundamentals as well as a solid balance sheet
Ypsomed has strong fundamentals as well as a solid balance sheet Net debt (as of 31 March) / EBITDA (from continuing operations the last 12 months) remains at a low level of 1.4x Ypsomed therefore continues to have a very solid balance sheet and can finance future organic growth from its own res
Slide 37: Outlook for the FY 2025/26
Outlook for the FY 2025/26 Ypsomed expects revenue growth of around 20 % and an EBIT between CHF 190 and 210 million in the continued Delivery Systems business for the 2025/26 financial year 37 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 38: 38 | Ypsomed Holding AG | Full year results 2024/25
38 | Ypsomed Holding AG | Full year results 2024/25
Slide 39: Thank you Betül Susamis Unaran – Departing Board Member
Thank you Betül Susamis Unaran – Departing Board Member Member of the Board of Directors since 2021 (until July 2, 2025) Chairwoman of the Innovation & Sustainability Committee Chief Commercial Officer at Unilabs 39 | Ypsomed Holding AG | Full year results 2024/25 PUBLIC
Slide 40: Marie-Pierre Zerr – Proposed new Board Member
Marie-Pierre Zerr – Proposed new Board Member Ypsomed proposes Marie-Pierre Zerr as new Board Member Current Vice President Global Process Engineering at Stellantis Degree in Chemical Engineering with a specialization in plastics technology 40 | Ypsomed Holding AG | Full year results 2024/25 P
Slide 41: We look forward to your questions.
We look forward to your questions.